European Hematology Association - 31st Congress, 2026 (EHA) 11 - 14 June 2026

Efficacy and safety of oral tetrahydrouridine-decitabine (NDec) in adults with sickle cell disease: results from the phase 2, global, randomized, parallel-group ASCENT1 trial

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.

Keywords

Sickle Cell Disease

Congress oral presentation

NDec

Are you a healthcare professional?